top of page

Cardiac Implants Names Mark A. Turco, M.D., as CEO

Jul 1, 2022

In addition, Dr. James Barry appointed as Chairman of Cardiac Implants' Board of Directors

American Canyon, Calif. – Sept. 1, 2022 – Cardiac Implants, LLC, a leader in the development of minimally invasive annuloplasty technology, has named healthcare and business executive Dr. Mark A. Turco as its new CEO, Cardiac Implants is developing the world's first transcatheter, complete-ring annuloplasty technology, called Tri-Ring™, to address the serious problem of tricuspid valve regurgitation.

Dr. Turco brings more than 30 years of academic, private, and public sector experience, including several years in operating roles at two large-cap medical device companies. Dr. Turco’s early career was spent as a high-volume interventional cardiologist prior to his transition to the medical device industry. As a practicing interventional cardiologist, Dr. Turco played a pivotal role in the development and ultimate acquisition of several medical devices currently being utilized in the field and brings a diversity of skills to Cardiac Implants’ leadership.

Dr. Turco’s clinical experience was instrumental in building out Covidien’s vascular platforms, which were key components of Medtronic’s $42 billion acquisition of Covidien. Dr. Turco brings leadership experience, operational and clinical expertise to Cardiac Implants at this critical time as the company accelerates enrollment in its FDA-approved early feasibility study and advances its pipeline, which includes advancement of the Tri-Ring™ technology. “I am honored to work with the great team at Cardiac Implants to deliver its revolutionary percutaneous annuloplasty technology to patients and providers in the rapidly evolving field of valvular heart disease,” Dr. Turco said. “The tricuspid valve, frequently referred to as the ‘forgotten valve,’ represents one of the biggest growth areas in the field of structural heart treatments. I firmly believe that the Cardiac Implants’ Tri-Ring™ annuloplasty device and its unique two-stage procedure will provide an excellent solution for patients currently suffering from tricuspid valvular disease.”

Cardiac Implants has also named Dr. James J. Barry as Chairman of its Board of Directors. Dr. Barry has more than 30 years of experience in the medical device industry as an executive and corporate board director. He is currently Principal Owner at Convergent Biomedical Group, LLC, a company providing advisor services to the life sciences industry. Dr. Barry is the author of multiple peer-reviewed publications and holds more than 40 U.S. and international patents.

“We are excited to have Dr. Turco join Cardiac Implants at this important juncture in the company,” stated Dr. Barry. “Dr. Turco’s extensive experience as an interventional cardiologist, a clinical trialist, as well as his leadership and operational roles in the medical device industry, make him the ideal person to lead us into a successful future.”


Cardiac Implants, LLC, is engaged in the development and clinical investigation of percutaneous transcatheter devices for the treatment of structural heart diseases. The first product under development is a percutaneous complete ring annuloplasty device for the treatment of patients with tricuspid regurgitation. The Tri-Ring™ device is the only one of its kind designed to specifically meet the mechanical and functional endpoints of surgical ring annuloplasty, currently the clinical gold standard for surgical valve repair.

Founded in 2013, Cardiac Implants is headquartered in American Canyon, CA, with principal R&D and manufacturing operations in American Canyon, CA and Yokneam, Israel. All products under development are investigational and for investigational use only and not approved for clinical use in any jurisdiction, including the United States.

bottom of page